KORU Medical Systems, Inc.
NASDAQ:KRMDMedical - Instruments & Supplies
+$0.06 today
- Market cap
- $149.64M
- Beta
- 0.42
- P/E (TTM)
- -80.2
- EPS (TTM)
- -$0.05
Volume 0.19M
Average 0.13M
KRMD Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
KORU Medical Systems, Inc.NASDAQ: KRMD
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue grows in line with its trailing trend
Q1 FY2026 cost of revenue of $4.73M rose 31.8% year over year, ahead of the +30.1% change in trailing-twelve-month cost of revenue. Sequentially, it rose 16.0% from the prior quarter. Over 3 fiscal years it compounded at +7.4% a year.
Context
- Cost of revenue amounted to 37.7% of revenue in FY2025, up 1.1 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +31.8% holds above the trailing-twelve-month pace of +30.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 15.52M USD
- Year-over-year change
- +26.1%
- 4-year CAGR
- +12.4%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.52M | +26.1% |
| FY2024 | 2024-12-31 | 12.31M | +4.3% |
| FY2023 | 2023-12-31 | 11.81M | -5.7% |
| FY2022 | 2022-12-31 | 12.53M | +28.9% |
| FY2021 | 2021-12-31 | 9.72M | — |
Cost of Revenue vs competitors
How KRMD compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +30.1% is the 5th highest of 10, against a peer median of +17.1%.
- Cost of revenue amounts to 38.5% of revenue for KRMD, versus a peer median of 43.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $78.91M USD | +141.8% | +70.6% | 52.0% | |
| LTM Mar 2026 | $66.66M USD | -28.2% | -34.6% | 59.0% | |
| LTM Mar 2026 | $61.59M USD | -4.5% | +8.6% | 43.3% | |
| LTM Mar 2026 | $47.41M USD | +110.1% | +65.9% | 41.7% | |
| LTM Mar 2026 | $17.4M USD | +0.1% | -2.4% | 46.4% | |
| LTM Mar 2026 | $16.67M USD | +30.1% | +7.4% | 38.5% | |
| LTM Mar 2026 | €8.43M EUR | +460.5% | +47.5% | 51.7% | |
| LTM Mar 2026 | $6.7M USD | +44.8% | +45.6% | 14.9% | |
| LTM Mar 2026 | $6.23M USD | -13.4% | +6.9% | 19.3% | |
| LTM Mar 2026 | $5.46M USD | +17.1% | +9.4% | 28.9% | |
| Peer median (excluding KRMD) | — | +17.1% | +9.4% | 43.3% | |
Competitors are the stored peer set for KRMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 23.49M | 27.9M | 28.52M | 33.65M | 41.13M |
| Cost of Revenue | 9.72M | 12.53M | 11.81M | 12.31M | 15.52M |
| Gross Profit | 13.77M | 15.37M | 16.71M | 21.33M | 25.6M |
| Gross Margin | 58.6% | 55.1% | 58.6% | 63.4% | 62.3% |
| Research & Development | 2.47M | 4.96M | 5.74M | 5.26M | 4.39M |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 23.38M |
| Operating Expenses | 20.8M | 26.15M | 26.98M | 27.78M | 28.58M |
| Depreciation & Amortization | 463.13K | 587.14K | 870.39K | 772.89K | 810.5K |
| EBITDA | (5.9M) | (10.09M) | (8.9M) | (5.29M) | (1.81M) |
| EBITDA Margin | -25.1% | -36.2% | -31.2% | -15.7% | -4.4% |
| Operating Income | (7.03M) | (10.78M) | (10.27M) | (6.45M) | (2.97M) |
| Operating Margin | -29.9% | -38.6% | -36.0% | -19.2% | -7.2% |
| Interest Income | 13.08K | 145.59K | 561.33K | 444.64K | 293.4K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 665.09K | 105.71K | 496.4K | 382.49K | 356.41K |
| Income Before Tax | (6.36M) | (10.68M) | (9.77M) | (6.06M) | (2.62M) |
| Pre-Tax Margin | -27.1% | -38.3% | -34.3% | -18.0% | -6.4% |
| Income Tax Expense | (1.8M) | (2.01M) | 3.97M | 2.89K | 21.89K |
| Net Income | (4.56M) | (8.66M) | (13.74M) | (6.07M) | (2.64M) |
| Net Margin | -19.4% | -31.0% | -48.2% | -18.0% | -6.4% |
| EPS (Basic) | (0.10) | (0.19) | (0.30) | (0.13) | (0.06) |
| EPS (Diluted) | (0.10) | (0.19) | (0.30) | (0.13) | (0.06) |
| Weighted Avg Shares | 44.39M | 45M | 45.6M | 45.8M | 46.19M |
| Weighted Avg Shares (Diluted) | 44.39M | 45M | 45.6M | 45.8M | 46.19M |
KORU Medical Systems, Inc.
NASDAQ:KRMD
Intrinsic Alpha fair value
Locked
Current Price
$3.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.